These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9284433)

  • 1. [Do angiotensin converting enzyme and calcium channel blocker intervene in the progression of renal disease besides by lowering systemic hypertension?].
    Nagase M
    Nihon Rinsho; 1997 Aug; 55(8):2116-22. PubMed ID: 9284433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic strategy for progressive renal disease].
    Hayashi K; Ozawa Y; Tokuyama H
    Nihon Rinsho; 2001 May; 59(5):955-60. PubMed ID: 11391998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ace inhibition in renal disease: risks and benefits.
    Campanacci L; Fabris B; Fischetti F; Bardelli M; Vran F; Carretta R
    Clin Exp Hypertens; 1993; 15 Suppl 1():173-86. PubMed ID: 8513308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and progression of renal disease.
    Maschio G; Oldrizzi L; Marcantoni C; Rugiu C
    J Nephrol; 2000; 13(3):225-7. PubMed ID: 10928300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence-based usefulness of Ca antagonists and ACEIs and ARBs for the primary and secondary prevention of major cardiovascular and renal events in patients with hypertension].
    Fujino T; Hasebe N; Kikuchi K
    Clin Calcium; 2005 Oct; 15(10):1695-708. PubMed ID: 16199917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hypertension in chronic renal insufficiency.
    Locatelli F; Manzoni C; Marcelli D
    J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic hypertension and antihypertensive agents.
    Maschio G; Marcantoni C; Bernich P
    J Nephrol; 1999; 12 Suppl 2():S100-4. PubMed ID: 10688408
    [No Abstract]   [Full Text] [Related]  

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive drugs in renal failure.
    Albert FW
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S108-12. PubMed ID: 7898089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.